Abstract We examined somatostatin receptor type 2A (SSTR2A) expression in primary and metastatic small intestinal neuroendocrine tumors (SI-NETs). We retrieved 156 liver metastases from 26 patients (10 males, 16 females) who had two or more liver lesions resected. A representative formalinfixed paraffin-embedded section of tumor tissue from each liver metastasis and from the primary tumor, when available, were immunohistochemically stained for SSTR2A. SSTR2A expression was evaluated by the Her2/neu-scoring system and the scoring system proposed by Volante et al. Based on the Her2/neu-scoring system, moderate to strong SSTR2A expression was observed in 121 of 156 (78%) liver metastases. In 15 (58%) subjects, all liver metastases showed moderate to strong SSTR2A expression, whereas in 11 (42%) one or more liver tumors had weak or no expression. Of the 16 stained primaries, 11 (69%) showed heterogeneous SSTR2A expression. The corresponding liver metastases showed only weak to no expression in one, moderate to strong in five, and both weak to no and moderate to strong expression in five of the 11 cases. Using the Volante scoring system, no tumor was scored 0 (0%), two were scored 1 (1%), 38 were scored 2 (24%), and 116 were scored 3 (74%). No statistically significant association was observed between SSTR2A expression and Ki67 index (p = 0.56). Fifteen of 18 (83%) metastatic tumors with a Ki67 index >20% showed moderate to strong SSTR2A. Most liver tumors with weak SSTR2A expression or an IHC score of 2 were detected by OctreoScan. SSTR2A expression in liver metastases of SI-NETs can be variable, even between lesions in the same patient. Expression in metastatic lesions is not always similar to that in the primary tumor. SSTR2A expression is not associated with the Ki67 index.
Introduction
Somatostatin receptors (SSTRs) are G-protein-coupled receptors that inhibit adenylate cyclase and cyclic adenosine monophosphate production upon ligand binding, consequently regulating cell cycle, cell proliferation, and hormone secretion [1] . Five subtypes, including SSTR1, SSTR2A, SSTR3, SSTR4, and SSTR5, have been characterized in humans, all of which have been detected in gastroenteropancreatic neuroendocrine tumors (NETs) [2] [3] [4] [5] . SSTR2A is the predominantly expressed SSTR in these tumors, including in those in the small intestine [5] [6] [7] [8] .
Most patients with small intestinal NET present with advanced or incurable disease at initial diagnosis [9, 10] . However, small intestinal NETs are usually well differentiated with a prolonged disease course. Medical management (other than surgical resection) is frequently needed in these patients but the therapeutic options are limited. Typical cytotoxic chemotherapy is ineffective in treating this disease. SSTRbased therapies have been shown to decrease NET hormone production, improve symptoms, and slow tumor growth in patients with unresectable small bowel NETs [11] [12] [13] [14] [15] [16] .
SSTR2A shows high affinity for somatostatin analogues (SSAs), such as octreotide and lanreotide [17] [18] [19] . SSAs are standard diagnostic and treatment tools for small intestinal NETs. For example, 111 In-DTPA-Octreoscan and the newly developed, more sensitive 68 Ga-based PET tracers are used to detect SSTR2A expressing NETs [20] [21] [22] [23] [24] . SSAs have been routinely used to control carcinoid syndrome caused by excess serotonin production in metastatic NETs [16] . In addition, peptide receptor radionuclide therapy (PRRT) using radiolabeled SSAs is a promising treatment option for metastasized or unresectable NETs [22, 25, 26] .
Although most well-differentiated NETs strongly express SSTR2A, poorly differentiated neuroendocrine carcinomas frequently display reduced SSTR2A expression. In addition, like other malignancies, small intestinal NETs exhibit tumor heterogeneity. In this study, we intended to determine how often SSTR2A expression was different between NET metastases and the corresponding primary tumor. We also wished to determine whether metastases with a higher proliferation rate (as measured by Ki67 staining) were less likely to express SSTR2A.
Materials and methods

Patient selection
Patients who underwent partial hepatectomy or wedge resection for liver metastases of small intestinal NETs between 2003 and 2013 were identified by reviewing the pathology department archives at Vanderbilt University Medical Center. Included in the study were patients who had two or more liver metastases that were resected at our institution. Twenty-six cases were identified with blocks available for immunohistochemical (IHC) studies. Of 16 of these cases also tumor tissue blocks from the primary tumor could be studied. Of all liver metastases included in the study Ki67 index and tumor size were available, as reported previously [27] . All included patients had a well-differentiated small bowel NET. Clinical histories, including preoperative octreotide treatment and imaging studies, were obtained from electronic medical records. This study was approved by the Vanderbilt Institutional Review Board.
SSTR2A and analysis
A 4-μm representative formalin-fixed paraffin-embedded tissue section from each liver tumor and available primary tumors was used for IHC for SSTR2A (Biotrend, Schwabhausen, Germany). The IHC stains were reviewed by two pathologists (MC and CS) without knowledge of the Ki67 or clinical course of the patient. Membranous SSTR2A expression was scored using the Her2/neu-scoring system as negative (0+), weak (1+), moderate (2+), and strong (3+) as shown in Table 1 [28, 29] or using the scoring system proposed by Volante et al. as shown in Table 2 [30] . Liver metastases were separated into two groups based on SSTR2A expression and assessed using the Her2/neu-scoring system: group 1 with weak to no expression and group 2 with moderate to strong expression. Cytoplasmic SSTR2A expression was also evaluated in the liver lesions.
Statistical analysis
Linear mixed-effect models were used to assess associations between SSTR2A expression and Ki67 index, and between SSTR2A expression and tumor size, accounting for withinpatient correlation due to multiple measurements per patient. In all models, logarithmically transformed Ki67 index and tumor size were used, and patient age and sex were included as covariates. Statistical analyses were conducted using R version 3.3 statistical software [31] . Student's t test and Fisher's exact test were used to compare membranous and cytoplasmic SSTR2A expression between octreotide-treated and untreated groups, respectively. All statistical tests were two-sided, and a p value <0.05 was considered statistically significant.
Results
General clinical and pathologic features
The 26 patients (10 males, 16 females) had a median age of 60 years (range 20 to 75 years, Table 3 ). A Ki67 index was available for 19 primary tumors from 19 patients including 16 in-house cases of which primary tumor blocks were available for Ki67 immunohistochemistry and 3 referral cases of which a Ki67 stain could be obtained for review. Based on the World Health Organization (WHO) 2010 classification of neuroendocrine neoplasms of the digestive tract [32] , these included 16 grade 1 (Ki67 ≤ 2%) and three grade 2 tumors (Ki67 ranging from 3 to 8%). A total of 156 liver lesions were resected from the 26 patients, 18 (12%) of which were grade 3 with a Ki67 index ranging from 21 to 31%. Overall, eight (31%) cases had one or more liver metastases that were grade 3 ( Table 3 ). The mean tumor number per patient was six, ranging from two to 12. Mean tumor size was 1.3 cm (range 0.1 to 5.6 cm; Table 3 ).
Expression of SSTR2A in liver metastases is heterogeneous
No, weak, moderate, and strong membranous SSTR2A expression, evaluated using the Her2/neu-scoring system, was seen in 4 (3%), 31 (20%), 39 (25%), and 82 (52%) of 156 liver tumors, respectively (Fig. 1a) . Based on membranous SSTR2A expression, liver tumors were classified as either group 1 (no to weak) or group 2 (moderate to strong) expression. Fifteen (58%) of 26 patients had group 2 tumors only, whereas three (11%) had group 1 tumors only. The remaining 8 (31%) patients had both group 1 and group 2 tumors (Fig. 1b , Table 3 ). Therefore, inter-tumor heterogeneity of SSTR2A expression in liver metastases was found in nearly one third of patients (Fig. 2) . Of note, the three cases with group 1 tumors only contained either WHO grade 1 or grade 2 liver tumors. Overall 42% (11/26) patients had one or more tumors that had no to weak SSTR2A expression on the plasma membrane.
Using the scoring system proposed by Volante et al. [30] , SSTR2A IHC scores of 2 and 3 were detected in 38 (24%) and 116 (74%) of the studied lesions, respectively. Only two liver metastases (1%) had cytoplasmic staining only (score 1), and none showed no staining at all. In the Volante scoring system, SSTR2A IHC scores of 2 and 3 are considered as positive [30] . In all 26 cases, at least one liver metastasis was positive for SSTR2A expression, nine of which (41%) had an IHC score of 3 in all liver lesions.
Comparison of SSTR2A expression between primary tumors and their liver metastases
Sixteen patients had a primary small bowel tumor available for SSTR2A. While 12 (67%) had moderate to strong, four (33%) had no to weak SSTR2A expression by the Her2/neuscoring system (Table 3) . Careful examination of SSTR2A expression showed that 11 of 16 (69%) primaries showed prominent heterogeneity in SSTR2A expression (Table 4) ; the same tumors contained >10% of tumor cells with no to weak expression and >10% with moderate to strong expression (Fig. 2a) . Liver metastases arising from these primaries were either group 1 only (1/11, 10%), group 2 only (5/11, 45%), or both (5/11, 45%, Fig. 2b-d) .
In three of 16 (19%) primaries, expression of SSTR2A was no to weak in more than 90% of tumor cells. Of these cases, two showed weak to no and one moderate SSTR2A expression in all liver tumors. In two more primaries (12%), moderate to strong SSTR2A expression was found in more than 90% of tumor cells. All liver lesions from the two cases also showed moderate to strong SSTR2A expression.
Based on the scoring system proposed by Volante et al. [30] , SSTR2A IHC scores for 16 primaries were either 2 (31%) or 3 (69%). The 11 primaries with an IHC score of 3 gave rise to liver metastases with a score ranging from 1 to 3. However, most (44/67, 66%) of their liver metastases had a score of 3. Five cases with a primary showing an IHC score of 2 had liver metastases that were either scored 2 or 3.
Association between SSTR2A expression and Ki67 index or tumor size Ki67 index and tumor size were compared between liver tumors with no to weak SSTR2A expression and those with moderate to strong expression. No statistically significant differences were observed in Ki67 index (p = 0.56) or tumor size (p = 0.14), while adjusting for patients' age and gender. In addition, there were no significant differences in Ki67 (p = 0.56) or tumor size (p = 0.14) between liver tumors scored 1-2 and those scored 3 by the Volante scoring system.
We hypothesized that high-grade neuroendocrine neoplasms loose SSTR2A expression on the cell membrane. We aimed to examine whether there was decreased SSTR2A expression in well-differentiated NETs with Ki67 index >20% (WHO grade 3). SSTR2A expression was compared between liver tumors with Ki67 ≤ 20% and those with Ki67 > 20%. No differences in SSTR2A expression between these 2 groups were found (p = 0.56); moderate to strong SSTR2A expression was detected in 15 of 18 (83%) liver tumors with Ki67 > 20% and in 104 of 138 (75%) liver tumors with Ki67 ≤ 20%. 
Correlation of SSTR2A expression with SSTR-based imaging and treatment
Twenty-one cases received preoperative OctreoScan (n = 20) and/or 68 Ga-DOTA-TATE PET-CT imaging studies (n = 2). Most of the liver lesions with weak SSTR2A expression by the Her2/neu-scoring system showed activity on OctreoScan. However, some small liver tumors (<1.0 cm) were negative on OctreoScan, regardless of whether they strongly or weakly expressed SSTR2A. In addition, one 1.7 cm primary tumor with weak SSTR2A expression was not detected by OctreoScan. On the other hand, all liver lesions in the two patients who had 68 Ga-DOTA-TATE PET-CT imaging studies showed activity, even when they were smaller than 1 cm and weakly expressed SSTR2A. Similar results were obtained when the SSTR-based imaging studies were correlated with SSTR2A expression evaluated using the Volante scoring system. Octreoscan detected most of the large liver lesions whether they had an IHC score of 2 or 3, whereas most of the small lesions (<1.0 cm) were not detected by Octreoscan even when the tumor had an IHC score of 3. Interestingly, the OctreoScan-negative, 1.7-cm primary tumor was scored as Bweak SSTR2A expression^by the Her2/neu-scoring system, but had a score of 3 by the Volante scoring system. Thirteen of 26 (50%) patients were treated with octreotide before surgical resection of the liver lesions. There was no difference in membranous SSTR2A expression between octreotide-treated and untreated tumors (p = 0.6). Cytoplasmic expression of SSTR2A was also 
Discussion
In this study, we systemically analyzed SSTR2A expression in primary small intestine NETs and their liver metastases. Small intestine NETs are generally considered to uniformly express SSTR2A. We found that SSTR2A expression was heterogeneous in two thirds of small intestine NETs (Table 4) and that SSTR2A expression was even heterogeneous between liver metastases in the same patient. In addition, SSTR2A expression in a primary tumor was not invariably similar to that in liver metastases. Furthermore, no significant association was observed between SSTR2A expression and Ki67 index, as the majority of tumors with a Ki67 index > 20% had moderate to strong expression of SSTR2A by the Her2/neu-scoring system. SSTR-based molecular imaging has been used widely to diagnose, stage, and follow-up NETs. One would assume that not every metastatic lesion can be detected by this technique, even in patients with a primary NET expressing SSTR2A, due to the common presence of SSTR inter-tumoral heterogeneity of the metastases. However, correlation of imaging findings and IHC results revealed that OctreoScan was able to detect most large liver tumors (≥1 cm) with weak SSTR2A expression. However, small-sized tumors even with strong SSTR2A expression might not be detected by OctreoScan. In this study, we had two patients whose tumors were staged by 68 GaDOTATATE PET-CT imaging. Several very small tumors (as small as 0.4 cm) with weak expression of SSTR2A were detected by 68 GaDOTATATE PET-CT imaging. Four liver lesions did not express SSTR2A by IHC. Unfortunately, SSTR-based imaging details of these lesions were not available. Nevertheless, our data suggest that sensitive SSTRbased imaging technologies such as 68 GaDOTATATE PET-CT imaging can detect the vast majority of liver metastases of small bowel NETs.
In patients with small intestine NET, SSA treatment has been shown to control carcinoid syndrome and prolong time to progression [15, 16, 25] . Multiple factors, such as tumor burden and receptor expression levels, may determine treatment effectiveness [33] . For example, PRRT with a radiolabelled analogue (e.g., 90 Y-DOTATOC or 177 Lu-DOTATATE) is a promising treatment option for stage IV NETs. It can deliver radiation doses into tumor cells via internalization through SSTR (mainly SSTR2A), achieving a partial and complete objective response in up to 50% of patients [34] [35] [36] . Some authors contend that response to PRRT is also correlated with SSTR2A expression and PRRT is only effective in the treatment of tumors with high membranous expression of SSTRs [22, 35] . Our data show that although the majority of liver metastases from small intestine NET had moderate to strong membranous SSTR2A expression, approximately a quarter of the liver lesions showed weak to no expression. SSA therapy may be less effective in treating lesions with low SSTR2A expression. Because of inter-tumoral heterogeneity, therapy efficacy may be different between tumors in the same patient. Multi-receptor targeting, especially for nonresponsive tumors, is being explored.
Multiple methods have been proposed to assess SSTR2A expression by IHC in NETs, including the Her2/neu-scoring system and the scoring system proposed by Volante et al. [28] [29] [30] . The latter was shown to have a good correlation with in vivo scintigraphic data. In this study, we used both the Her2/neu-scoring system and the Volante scoring system to evaluate SSTR2A expression in small intestine NETs and their liver metastases. It appeared that both systems have the same limitation in predicting OctreoScan activity in detecting small liver lesions. In addition, both systems identified a small but significant proportion of liver metastases with negative to weak SSTR2A expression or with a SSTR2A IHC score of 0-2. This identification is potentially useful in predicting effectiveness of SSA-based treatment as tumors with weaker SSTR2A expression may be less responsive to the treatment.
PRRT has only been used to treat WHO grade 1 and WHO grade 2 tumors, because it has been assumed that there is reduced SSTR expression in higher-grade tumors [37, 38] . Our study shows that all 19 primaries were either grade 1 or 2 by Ki67 index, but more than 10% of the liver metastases were grade 3 (Ki67 > 20%) based on these 2010 WHO criteria. Korner et al. reported some reduction in SSTR2A expression in seven gastrointestinal neuroendocrine neoplasms with a Ki67 index >20% [39] . However, we found that, similar to grade 1 and grade 2 tumors, most grade 3 liver tumors (well-differentiated NETs with Ki67 index >20%) had moderate to strong membranous SSTR2A expression. Therefore, PRRT may still be considered as a treatment option for well-differentiated NETs with a Ki67 > 20%. Although the current WHO classification defines digestive tract NETs with a Ki67 > 20% as poorly differentiated neuroendocrine carcinomas, there are some morphologically well-differentiated NETs with a Ki67 index >20%, even up to 30% as shown in this study. Grade 3 well-differentiated NETs might be managed similar to grade 1 or 2 NETs. Therefore, the current WHO classification needs to be modified to more accurately grade NETs.
Upon binding to SSA, SSTR2A undergoes internalization, trafficking and recycling of the receptor back to the cell membrane. An open question is whether SSA treatment affects distribution or expression of SSTR2A? We studied this in 13 of 26 patients who were treated with octreotide before surgery. Membranous SSTR2A expression was not different between octreotide-treated and untreated liver lesions. Treated lesions tended to show cytoplasmic expression more often than untreated lesions but this difference was not statistically significant.
In conclusion, the expression of SSTR2A in small intestine NETs and their liver metastases is heterogeneous both at intratumoral and inter-tumoral level, which may be responsible for differences in response to SSTR-based treatment between Compliance with ethical standards The study was reviewed and approved by the Vanderbilt Institutional Review Board. Consent was not required for this study.
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